Large-scale Testing of BRCA Mutations Can Be Cost-Effective, Study Finds

Large-scale Testing of BRCA Mutations Can Be Cost-Effective, Study Finds
Screening the overall population for mutations in the genes BRCA1 and BRCA2 that can cause breast and ovarian cancer is cost-effective in wealthier countries, from the viewpoint of both payers and society, an economic analysis study suggests. But these screenings are still too expensive to be cost-effective in less wealthy countries under such an analysis. "We must invest in cancer prevention — this is what will save most lives and also be cost effective within cash-strapped healthcare systems," Athena Lamnisos, CEO of the U.K. charity Eve Appeal, which supported the study, said in a press release. The study, "Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems," was published in Cancers. Inheritable mutations in BRCA1 and BRCA2 cause
Subscribe or to access all post and page content.